Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: \(<= 2\), pT2: \(> 2-<= 4\), pT3: \(> 4\) cm) is More Valid and Clinically Relevant

Burcu Saka, Emory University
Serdar Balci, Emory University
Olca Basturk, Wayne State University
Pelin Bagci, Marmara University
Lauren M. Postlewait, Emory University
Shishir Maithel, Emory University
Jessica Knight, Winship Canc Inst
Bassel El-Rayes, Emory University
David Kooby, Emory University
Juan Sarmiento, Emory University

Only first 10 authors above; see publication for full author list.

**Journal Title:** Annals of Surgical Oncology  
**Volume:** Volume 23, Number 6  
**Publisher:** Springer Verlag (Germany) | 2016-06-01, Pages 2010-2018  
**Type of Work:** Article | Post-print: After Peer Review  
**Publisher DOI:** 10.1245/s10434-016-5093-7  
**Permanent URL:** https://pid.emory.edu/ark:/25593/s16mz

Final published version: [http://dx.doi.org/10.1245/s10434-016-5093-7](http://dx.doi.org/10.1245/s10434-016-5093-7)

**Copyright information:**

© 2016, Society of Surgical Oncology. The final publication is available at Springer via [http://dx.doi.org/10.1245/s10434-016-5093-7](http://dx.doi.org/10.1245/s10434-016-5093-7)

Accessed January 23, 2019 4:50 PM EST
Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2–≤4, pT3: >4 cm) is More Valid and Clinically Relevant

Burcu Saka, MD1,8, Serdar Balci, MD1,9, Olca Basturk, MD2,10, Pelin Bagci, MD3, Lauren M. Postlewait, MD4, Shishir Maithel, MD4, Jessica Knight, MPH5, Bassel El-Rayes, MD6, David Kooby, MD7, Juan Sarmiento, MD7, Takashi Muraki, MD, PhD1, Irma Oliva, MD1, Sudeshna Bandypadhyay, MD2, Gizem Akkas, MD1, Michael Goodman, MD, PhD5, Michelle D. Reid, MD, MS1, Alyssa Krasinskas, MD1, Rhonda Everett, MPH, MLIS1, and Volkan Adsay, MD1

1Department of Pathology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA
2Department of Pathology, Wayne State University and Karmanos Cancer Institute, Detroit, MI
3Department of Pathology, Marmara University, Istanbul, Turkey
4Department of Surgical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA
5Department of Epidemiology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA
6Department of Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA
7Department of General Surgery, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA
8Istanbul Medipol University, Istanbul, Turkey
9Yildirim Beyazit University, Ankara, Turkey
10Memorial Sloan Kettering Cancer Center, New York, NY

Burcu Saka and Serdar Balci have contributed equally to the study.

Presented in part at the annual meeting of the United States and Canadian Academy of Pathology, March 2014, at San Diego, CA, USA.

Electronic supplementary material
The online version of this article (doi:10.1245/s10434-016-5093-7) contains supplementary material, which is available to authorized users.

DISCLOSURE
Volkan Adsay has a Grant from National Institutes of Health (#5P50 CA62924). Lauren M. Postlewait has received funding from the Katz Foundation. For the remaining authors none were declared. This study is also supported in parts by funds generously donated by Monastra Foundation.
Abstract

**Background**—Most studies have failed to identify any prognostic value of the current T-stage protocol for pancreatic ductal adenocarcinoma (PDAC) by the American Joint Committee on Cancer and the Union for International Cancer Control unless some grouping was performed.

**Methods**—To document the parameters included in this T-stage protocol, 223 consecutive pancreatoduodenectomy specimens with PDAC were processed by a uniform grossing protocol.

**Results**—Peripancreatic soft tissue (PST) involvement, the main pT3 parameter, was found to be inapplicable and irreproducible due to lack of a true capsule in the pancreas and variability in the amount and distribution of adipose tissue. Furthermore, 91% of the cases showed carcinoma in the adipose tissue, presumably representing the PST, and thus were classified as pT3. An additional 4.5% were qualified as pT3 due to extension into adjacent sites. The T-stage defined as such was not found to have any correlation with survival \((p = 0.4)\). A revised T-stage protocol was devised that defined pT1 as 2 cm or smaller, pT2 as >2–4 cm, and pT3 as larger than 4 cm. This revised protocol was tested in 757 consecutive PDACs. The median and 3-year survival rates of this size-based protocol were 26, 18, 13 months, and 40%, 26%, 20%, respectively \((p < 0.0001)\). The association between higher T-stage and shorter survival persisted in N0 cases and in multivariate modeling. Analysis of the Surveillance, Epidemiology, and End Results database also confirmed the survival differences \((p < 0.0001)\).

**Conclusions**—This study showed that resected PDACs are already spread to various surfaces of the pancreas, leaving only about 4% of PDACs to truly qualify as pT1/T2, and that the current T-stage protocol does not have any prognostic correlation. In contrast, as shown previously in many studies, size is an important prognosticator, and a size-based T-stage protocol is more applicable and has prognostic value in PDAC.

The current T-stage protocol for pancreatic ductal adenocarcinoma (PDAC) by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) (7th edition) uses tumor size for the early stages of tumor (pT1: ≤2 cm; pT2: >2 cm) and describes pT3 as the spread of the tumor beyond the pancreas, with this further defined as peripancreatic soft tissue (PST) involvement, common bile duct (CBD) involvement, or extension to the duodenum.1

Most major studies investigating the prognostic factors in PDAC have failed to identify the prognostic relevance for this T-stage2–5 unless regrouping was performed. Moreover, the type of grouping used to achieve statistical significance has varied from study to study, with some studies advocating pT1/pT2 vs pT3/pT46–10 and others combining pT1, pT2, and pT3 vs pT411,12 or combining Tis, pT1, and pT2 vs pT3 vs pT4.13 It is not clear whether the failure of the current T-stage system is due to the variability in interpretation of the parameters, the clinical insignificance of the parameters selected, or both.

In this study, the applicability and prognostic relevance of the main T-stage parameters in the current AJCC protocol were analyzed both through a critical analysis of the current guidelines and prospectively in a well-characterized cohort of 223 PDACs subjected to a uniform grossing pathologic documentation protocol.14,15 The findings showed that the current T-stage scheme is inapplicable and insignificant. Therefore, a size-based protocol
was devised and tested on 757 consecutive PDACs in our institutional databases and on
10,554 PDACs in the SEER database and found to have significant prognostic correlation.

METHODS AND DESIGN

Assessment of the Current Guidelines on T-Stage Parameters

The definitions provided in the main texts on the topic including the UICC/AJCC staging
book (7th edition), the cancer synoptic webpage of the College of American Pathologists
(CAP), documents prepared by American College of Surgeons, the World Health
Organization (WHO) classification of tumors of the digestive system, and the AFIP
fascicle were evaluated.

Cases for the Analysis of Current T-Stage Parameters

In this study, 223 consecutive pancreatoduodenectomies containing PDAC were
prospectively processed according to a uniform grossing protocol (see later) designed to
allow proper documentation of the pertinent T-stage parameters. To have a more
uniform cohort, the study included only conventional PDACs without any neoadjuvant
therapy that had undergone pancreatoduodenectomy at Emory and Wayne State Universities
and were grossed by the authors personally. The complete pathology material of the cases
was re-reviewed by three pathologists to confirm pertinent parameters. Unusual pancreatic
adenocarcinoma variants such as colloid were excluded as well as nonductal tumors (acinar,
neuroendocrine, pancreatoblastoma, solid pseudopapillary tumors) and secondary cancers
(e.g., ampullary, CBD cancers) using stringent criteria.

Sampling Protocol

The grossing protocol used for this purpose has been described in detail in other publications
and bears negligible cost. Briefly, it is a standardized approach in which the soft tissues
covering the pancreatic head are removed before dissection of the pancreatic head. This
approach can be adopted and used with ease by ordinary gross room personnel in a
conventional gross room using routine procedures. An important part of this protocol is the
orange-peeling of the soft tissues covering the pancreas, which are presumed to be the
closest representation of PST. In each case, the CBD is opened in the plane that goes through
both the CBD and the main pancreatic duct to establish the interaction of the tumor with
these two ducts. Similarly, the tumor invasion of the duodenum or ampulla is documented
per standard grossing protocols. The size of the invasive carcinoma is routinely documented
in pathology gross rooms.

A Size-Based Staging Protocol

During this study, the current parameters that define pT3 (e.g., PST or CBD involvement;
see Supplemental Text) were found to be inapplicable or prognostically irrelevant (see
“Results” Section). Therefore, a size-based definition of pT3 was devised, with pT3 defined
as a tumor larger than 4 cm.

Because the median size of the tumors in this study was 3.2 cm (see “Results” section) and
because a cutoff of 3 cm might provide more significance, it was thought that because 2 cm
is already used to define pT1 versus pT2 in the AJCC/UICC tumor-node-metastasis (TNM) staging, a cutoff of 4 cm would be more appropriate for pT3. This also parallels the European Neuroendocrine Tumour Society (ENETS) T-stage scheme for pancreatic neuroendocrine tumors (NETs), which findings have found to be a stronger prognosticator of NETs than the AJCC/UICC T-stage. Because most authors believe that pT4 is to be reserved for unresectable cases\textsuperscript{1} or cases that require more than a classic pancreatoduodenectomy operation, we kept pT1 to pT3 for the resected cases analyzed in this study.

This size-based staging system was tested with 757 consecutive PDACs, including the well-characterized cohort of 223 cases resected at Emory and Wayne State Universities between 2004 and 2013. Tumor size information was obtained from the pathology reports.

Analysis of SEER Database

For comparison with the clinical cohort, data on patients with pancreatic cancer were obtained from structured queries of the publicly available SEER database. Our analysis included PDACs diagnosed between 2004 and 2010. Cases without complete information on clinicopathologic characteristics relevant to survival were excluded, resulting in a sample of 10,554 cases.

Statistical Analyses

Kaplan–Meier survival curves were estimated and compared between all T-stages using the log-rank test. Survival time for all analyses was set at zero after the first 3 months of follow-up evaluation. This was done to avoid bias because individuals with less than 3 months of follow-up evaluation were excluded from the study.

Multivariate analysis was conducted using Cox proportional hazard models, with adjustment for age, sex, AJCC N-stage, margin status, and lymphovascular/perineural invasions. The proportional hazard assumption was evaluated using log–log survival curves. To evaluate the discriminatory power of the models, the concordance probability estimate (CPE) and Akaike’s Information Criterion (AIC) were calculated.\textsuperscript{21} All analyses were conducted using SAS software version 9.3 (SAS Institute, Cary, NC) and SPSS version 22 (IBM Corp., Armonk, NY), except for the CPE, which was calculated using the CPE package in R (R Core Team, Vienna, Austria).

RESULTS

Study Population

The study enrolled 223 patients with ordinary PDAC, all processed according to the uniform grossing protocol defined earlier. The mean age of the patients was 66 years (range 33–87 years), and 57 % of the patients were female (n = 126). The median tumor size was 3.2 cm (range 0.7–7 cm). The majority of the patients (78 %) had lymph node metastasis (pN1). The follow-up period ranged from 3.2 to 154 months (median 18 months). At the last follow-up visit, 139 of the patients (62 %) had died of disease, and 84 (38 %) were alive with disease (Table 1).
PST Involvement

In 91% of the cases, foci of carcinoma were identified in the orange-peeled PST. The highest incidence (58%) was detected in the PST of the uncinate (superior mesenteric artery) margin (Table 2).

In 48% of the cases, the foci of the carcinoma were insidious and away from the main tumor, represented as isolated solitary (naked) ducts. These ducts were either deceptively benign-appearing or mimicking pancreatic intraepithelial neoplasia (PanIN)22 (Supplemental Fig. 2). Notably, some of these foci gave the impression of intravascular spread. The involvement of PST was not found to have any statistical correlation with clinical outcome (p = 0.9).

CBD Involvement

When defined as any part of CBD, 97% of the PDACs were found to have CBD involvement, rendering this parameter irrelevant.22 If defined as extra-pancreatic part of CBD, then CBD involvement seemed to be present in 5% of the cases. Regardless, CBD involvement was found to have no prognostic impact (p = 0.9).

Duodenum/Ampulla Involvement

Neither duodenum involvement (74%) nor ampullary involvement (50%) (with muscularis involvement included) was found to have any association with clinical outcome (p = 0.89 and 0.14, respectively).

Testing of the Current T-Stage Protocol

With PST involvement defined as the presence of carcinoma foci in the orange-peeled soft tissues, CBD involvement defined as extra-pancreatic, and duodenum involvement defined as including muscularis, 95.5% of the PDAC cases in this study had to be classified as pT3, leaving only 1.8% of the cases to qualify as pT1 and 1.8% as pT2. This staging system had no prognostic value because the 1-year survival rates for pT1 vs pT2 vs pT3 vs pT4 were respectively 75, 75, 65, and 50%, and the 3-year survival rates were respectively 25, 0, 28, and 0% (p = 0.4).

Testing of the Size-Based T-Stage Protocol

When pT1 was defined as 2 cm or smaller, pT2 as >2 to 4 cm, and pT3 as larger than 4 cm and tested in 223 ordinary PDACs, they broke down into respective categories of 13, 64, and 23%. The median overall survival times in this cohort were respectively 27, 24, and 9 months. The 1-year survival rates were respectively 79, 69, and 47%, and 3-year survival rates were respectively 37, 28, and 21% (p = 0.004). However, the difference between pT1 and pT2 did not reach statistical significance due to the small number of T1 cases (p = 0.5).

For this reason, the proposed size-based T-staging protocol also was tested in 757 consecutive ordinary PDACs. The distributions of pT1, pT2, and pT3 in this cohort were respectively 20, 56, and 24%, and the median overall survival periods were respectively 26, 17.5, and 13 months. The 1-year survival rates were respectively 75, 67, and 51%, and the
3-year survival rates were respectively 40, 26, and 20 % (p < 0.0001 for pT1 vs pT2 vs pT3; p = 0.002 for pT1 vs pT2; p < 0.0001 for pT1 vs pT3; and p = 0.01 for pT2 vs pT3).

Lymph node status information was available in 476 cases. When cases without lymph node metastasis (n = 180) were analyzed separately, the prognostic significance persisted. The median overall survival times for pT1 vs pT2 vs pT3 were respectively 38, 18, and 12.5 months. The 1-year survival rates were respectively 82, 72, and 52 %, and the 3-year survival rates were respectively 51.5, 28, and 10 % (p < 0.0001 for pT1 vs pT2 vs pT3; p = 0.04 for pT1 vs pT2; p < 0.0001 for pT1 vs pT3; and p = 0.002 for pT2 vs pT3) (Table 3, Fig. 1). Analysis of the SEER database confirmed the survival differences between these T-stages, although the pT3 group had crossover for pT2. The median overall survival times for pT1 vs pT2 vs pT3 were 24, 15, and 14 months. The 1-year survival rates were respectively 70, 58, and 53 %, and the 3-year survival rates were respectively 39, 25, and 28 % (p < 0.0001 for pT1 vs pT2 vs pT3; p < 0.0001 for pT1 vs pT2; p < 0.0001 for pT1 vs pT3; and p = 0.6 for pT2 vs pT3).

The results were similar when separate analyses were performed for cases without lymph node metastasis. The median overall survival periods for pT1 vs pT2 vs pT3 were respectively 36, 21, and 21 months. The 1-year survival rates were 77, 64, and 64 %, and the 3-year survival rates were respectively 50, 35, and 38 % (p < 0.0001 for T1 vs T2 vs T3; p < 0.0001 for pT1 vs pT2 vs pT3; p < 0.0001 for pT1 vs pT2; p < 0.0001 for pT1 vs pT3; and p = 0.4 for pT2 vs pT3) (Table 4, Fig. 2).

In the multivariable Cox regression model adjusted for age, sex, N-stage, margin status, and lymphovascular/perineural invasions, the association between a higher proposed T-stage and shorter survival persisted. Using the T1 group as the reference, the adjusted hazard ratios (HRs) and 95 % confidence intervals (CIs) for T2 and T3 were respectively 1.03 (0.60–1.78) and 1.83 (CI 0.99–3.38) for all the cases in our cohort (p = 0.01). In these models, age also was statistically significantly associated with survival. The HR was 1.2 (95 % CI 1.0–1.4; p = 0.02) for a 10-year increase in age.

The multivariate analysis of the SEER database included age, sex, and N-stage. In these analyses, using the T1 group as the reference, the adjusted HR and 95 % CI were 1.39 (1.28–1.50) for T2 and 1.47 (1.35–1.60) for T3 (p < 0.0001).

**DISCUSSION**

In this study, the applicability and clinical relevance of the current T staging was investigated in a well-characterized and stringently defined cohort of ordinary PDAC patients who had undergone pancreatoduodenectomy and had been processed according to a protocol allowing the documentation of the spread patterns of PDAC. The findings showed that even after the definitional ambiguities are overcome, the current AJCC/UICC T staging for the pancreas is both impractical and lacks prognostic correlation.

An analysis of the current guidelines indicates that one of the main parameters defining T3 spread beyond the pancreas is primarily defined as involvement of PST. As this study further discovered, PST is not a well-defined structure. Also, because PDACs are highly...
insidious tumors with subtle spread patterns, proper documentation of the true PST either requires extensive perpendicular sampling (as advocated by Verbeke and Esposito/Schlitter protocols\textsuperscript{23–25}), which is costly and time consuming, or necessitates shaved removal and examination of the soft tissues covering the pancreatic head using a method such as orange-peeling.\textsuperscript{14,15} In this study, the latter approach showed that these soft tissues covering the pancreas are involved in more than 90 \% of the resected PDACs in the head. Together with other parameters discussed later, this leaves only about 4 \% of cases to qualify as pT1/pT2, thus negating the usability of the current T staging.

Naturally, in the vast majority of the literature, the reported incidence of T1 and T2 is much higher than in our study\textsuperscript{2,26–30} because proper sampling of PST was not performed as in our study with the orange-peeling approach. In most pathology laboratories, because random sampling is used to document PST, a significant proportion of cases get understaged as T1/T2 because soft tissue involvement is missed. Therefore, it can be safely assumed that the extent of tumor infiltration into PST is a factor of larger tumor size, so it is not surprising that in studies with random sampling of PST, incidental discovery of carcinoma in these sections correlates with the outcome as a reflection of larger tumors.\textsuperscript{31} However, our study illustrates that with careful sampling and documentation, the true PST is in fact involved with carcinoma in 91 \% of PDACs. Furthermore, the involvement of PST was not found to have any significant association with prognosis. This also accords with reports in the literature that in most major studies, no linear correlation could be documented between the current T-stage protocol and prognosis unless some regrouping was performed to achieve significance.\textsuperscript{2,6–13}

The commonness of PST involvement, especially with carcinomatous foci away from the main tumor, also highlights the fact that PDACs typically are spread far beyond what meets the eye at the time of diagnosis, commonly and extensively involving the soft tissues covering the pancreas. This “horses-out-of-the-barn” phenomenon most likely is also responsible for the rapid recurrence and dissemination of pancreatic cancer seen in virtually all cases. At the same time, however, considering that resected PDACs have an incomparably longer survival than nonresected cases,\textsuperscript{32} this may argue in favor of performing pancreatoduodenectomy even for borderline resectable cases.\textsuperscript{33–35}

The analysis of the current staging guidelines also highlights the challenges in applicability of the remaining pT3-defining parameters as well. For example, CBD involvement is interpreted variably in different guideline documents, with some advocating the inclusion of any CBD segment,\textsuperscript{1} and others stating only extra-pancreatic biliary involvement as the sole criterion.\textsuperscript{18} Both definitions present their own applicability challenges. Defining CBD involvement as extra-pancreatic requires a “magic bullet” spread, whereas involvement of the mid-proximal CBD, which is extra-pancreatic, requires extensive local spread of the tumor, rendering it unresectable and thus not amenable to pT staging or entailing intramural spread through the CBD wall, intramucosally or through the perineural spread, which indicates the diagnosis of primary CBD carcinoma instead. Additionally, no good definition of extra-pancreatic CBD exists because CBD has a variable pancreatic covering depending on the individual and the sampling. Moreover, most sampling protocols do not specifically focus on the extra-pancreatic CBD, except for the CBD margin. If, instead, the entire CBD,
including the intra-pancreatic compartment, is regarded as the criterion for pT3, then it is
involved in 97% of the cases, essentially rendering it an irrelevant parameter for
stratification purposes.

Thus, this study fundamentally shows what has already been noted in the literature regarding
the lack of linear prognostic correlation for the AJCC/UICC T staging for pancreatic head
cancers of the ordinary PDAC type. However, it also shows that the main reason for this
failure is the applicability and irreproducibility of the pT3 parameters as defined currently.

One potential T-stage model that can replace the current inapplicable one is the model based
on size, which already is the main defining parameter for T1 and T2 in the pancreas. This
model also has been used very successfully with many solid organ cancers, including breast
and lung cancers. Numerous studies also have found it to be a strong prognosticator in
PDACs. Actually, in many major studies investigating the prognostic factors in PDACs, size
stands out as one of the most important parameters. The number that seems to be
recurrent in these studies as a stratifier is 3–3.5 cm, which essentially is the
median size of tumor in resected cancers. Therefore, a cutoff of 4 cm to define T3 appears to
be the most logical. This also is the cutoff adopted by ENETS for T staging of pancreatic
NETs. Defined as such in this study, 13% of the PDACs fell into the pT1 category and
64% into the pT2 category, compared with the about 4% categorization as pT1/T2 together
in the current T-stage classification. Notably, the median size of the invasive carcinoma in
the current study (3.2 cm) and the percentage of tumors smaller than 2 cm are very
comparable with those reported in other large institution-based studies. In Japan, this
figure is consistently reported to be about 10%, presumably due to more careful grossing
protocols. However, in the SEER database and ESPAC publications, the percentage
of small cancers seems to be much higher than in these institutional cohorts, which is
presumably attributable to the mis-recordings of non-PDAC cancers such as intraductal
papillary mucinous neoplasm-associated carcinomas in the SEER database and other
nonpathologically verified databases.

This size-based T-stage, unlike the current T-stage classification, was found to be highly
significant prognostically both in our institutional cohort and in the SEER database (Figs. 1
and 2), as well as in a multivariate model. The prognostic significance persists in cases
without lymph node metastasis as well. Although the survival difference between T1 and T2
in our well-characterized cohort of 223 cases did not reach statistical significance due to
small numbers; the separation of T1 and T2 was highly significant both in our larger cohort
of 757 PDACs and in the SEER database. The survival of T3 versus T2 also was greatly
different in our institutional cohort, whereas in the SEER database, the pT3 group had the
rather expected cross over the pT2 due to the inclusion of benevolent cancer types (e.g.,
acinar, pancreatoblastoma, solid-pseudopapillary cancers), selectively clustering in the T3
group due to their commonly large size at presentation.

It should be noted that different approaches have been used for pathologic examination of
pancreatic specimens. However, it does not matter which grossing approach is used as
long as proper sampling of PST is performed and complete harvesting of lymph nodes is
achieved. Our protocol is a very straightforward one that involves separation of PST before
cutting of the pancreatic head to avoid underevaluation of this tissue, and this method currently is used in many institutions. This proper sampling of PST accounts for the higher percentage of current AJCC pT3 cases in our institutional cohort (96 %). Similarly, before establishment of this approach, the median number of regional lymph nodes examined in our own institutions was very low (respectively 6 and 7 in our two institutions and also similar to the median number of 7 in the SEER database). Currently, with the orange-peeling approach, our median lymph node number of 17 is similar to those reported from most experienced and high-volume institutions.

The application of a better lymph node harvesting approach also may account for the higher lymph node metastasis rate in our institutional cohort (79 %) than the rates recorded in SEER (60 %, Table 1), CONKO (70 %),26,27 and ESPAC (54 %),28,29 as well as for the higher percentage of pN2 cases60 (pN1: 26 %; pN2: 51 %) than in the SEER database (pN1: 33 %; pN2: 27 %). Notably, a careful review of the literature shows that the data from high-volume institutions also have a lymph node metastasis rate of nearly 80 %.

Naturally, we recognize that moving to a different staging system has implications and comes with its challenges, such as hampered comparison with earlier data. On the other hand, it is very clear that virtually no institution-based studies have been able to confirm a direct and linear correlation for the current AJCC T staging. Thus, without question, we need an applicable and clinically relevant T-staging system for the pancreas.

In summary, this study demonstrated that PDACs are found to be spread beyond what meets the eye when proper dissection and careful microscopic examination is performed, which also renders the current T staging of PDACs by AJCC/UICC as impractical, with only about 4 % of cases qualifying as pT1 and pT2. The current AJCC T staging also has no prognostic correlation, as amply demonstrated in the literature and in this study. Therefore, a different T-staging protocol was devised that defines pT1 as 2 cm or smaller, pT2 as >2–4 cm, and pT3 as larger than 4 cm. This proposed T-staging protocol was found to have linear prognostic value and should be used to replace the current T-staging protocol.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References


FIG. 1.
Comparison of survival between proposed (size-based) T-stages in the institutional cohort. 
Left All cases. Right Cases without lymph node metastasis (pN0)
FIG. 2.
Comparison of survival between proposed (size-based) T-stages in the Surveillance, Epidemiology, and End Results (SEER) database. Left All cases. Right Cases without lymph node metastasis (pN0)
TABLE 1

Clinicopathologic features of the cases

<table>
<thead>
<tr>
<th></th>
<th>Institutional cohort (n = 223) n (%)</th>
<th>SEER database (n = 9296) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>126 (56.5)</td>
<td>4639 (50)</td>
</tr>
<tr>
<td>Male</td>
<td>97 (43.5)</td>
<td>4657 (50)</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>66 (33–87)</td>
<td>66 (4–85)</td>
</tr>
<tr>
<td>Mean</td>
<td>65</td>
<td>65</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>3.2</td>
<td>3.3</td>
</tr>
<tr>
<td>Mean</td>
<td>3.3</td>
<td>3.7</td>
</tr>
<tr>
<td>AJCC T staging</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>4 (1.8)</td>
<td>655 (7)</td>
</tr>
<tr>
<td>T2</td>
<td>4 (1.8)</td>
<td>1697 (18)</td>
</tr>
<tr>
<td>T3</td>
<td>213 (95.5)</td>
<td>6207 (67)</td>
</tr>
<tr>
<td>T4</td>
<td>2 (0.9)</td>
<td>737 (8)</td>
</tr>
<tr>
<td>Proposed T staging</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1 (&lt; 2 cm)</td>
<td>29 (13)</td>
<td>1573 (17)</td>
</tr>
<tr>
<td>T2 (&gt; 2 to ≤ 4 cm)</td>
<td>142 (64)</td>
<td>5097 (55)</td>
</tr>
<tr>
<td>T3 (&gt; 4 cm)</td>
<td>52 (23)</td>
<td>2626 (28)</td>
</tr>
<tr>
<td>AJCC N staging</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>49 (22)</td>
<td>3756 (40)</td>
</tr>
<tr>
<td>N1</td>
<td>174 (78)</td>
<td>5540 (60)</td>
</tr>
<tr>
<td>LNs examined</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>18 (3–45)</td>
<td>11 (1–89)</td>
</tr>
<tr>
<td>LNs with metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>3 (1–20)</td>
<td>2 (1–47)</td>
</tr>
<tr>
<td>Outcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dead</td>
<td>139 (62)</td>
<td>5636 (61)</td>
</tr>
<tr>
<td>Alive</td>
<td>84 (38)</td>
<td>3660 (39)</td>
</tr>
<tr>
<td>Survival (months)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>18</td>
<td>16</td>
</tr>
</tbody>
</table>

Institutional cohort processed according to a uniform grossing protocol, with authors confirming the diagnosis/stage by re-reviewing the entire pathology material

SEER Surveillance, Epidemiology, and End Results, AJCC American Joint Committee on Cancer, LN lymph node
TABLE 2
Frequency of local spread patterns of ordinary pancreatic ductal adenocarcinomas (PDACs) analyzed in 223 cases by careful grossing

<table>
<thead>
<tr>
<th>Spread location</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBD (any part of CBD)</td>
<td>97</td>
</tr>
<tr>
<td>CBD (extra-pancreatic)</td>
<td>5</td>
</tr>
<tr>
<td>Duodenum</td>
<td>74</td>
</tr>
<tr>
<td>Ampulla</td>
<td>50</td>
</tr>
<tr>
<td>Peripancreatic soft tissue(^d)</td>
<td>91</td>
</tr>
<tr>
<td>Uncinate (SMA) margin</td>
<td>58</td>
</tr>
<tr>
<td>Superior pancreatic</td>
<td>20</td>
</tr>
<tr>
<td>Anterior pancreatic</td>
<td>29</td>
</tr>
<tr>
<td>Anterior pancreaticoduodenal</td>
<td>19</td>
</tr>
<tr>
<td>Posterior pancreatic</td>
<td>23</td>
</tr>
<tr>
<td>Posterior pancreaticoduodenal</td>
<td>19</td>
</tr>
<tr>
<td>Inferior pancreatic</td>
<td>16</td>
</tr>
<tr>
<td>LN metastasis</td>
<td>79</td>
</tr>
</tbody>
</table>

CBD common bile duct, SMA superior mesenteric artery, LN lymph node

\(^d\)Peripancreatic soft tissue: adipose tissue covering the pancreas removed during the orange-peeling approach for LN harvesting; does not represent complete or perpendicular sampling
TABLE 3

Median survivals for proposed (size-based) T-stages (institutional cohort)

<table>
<thead>
<tr>
<th></th>
<th>All cases</th>
<th></th>
<th>N0 cases</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>T1 (≤2 cm)</td>
<td>T2 (&gt;2 to ≤4 cm)</td>
<td>T3 (&gt;4 cm)</td>
<td>p Value</td>
</tr>
<tr>
<td>n (%)</td>
<td>151 (20)</td>
<td>421 (56)</td>
<td>185 (24)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Median (months)</td>
<td>26</td>
<td>17.5</td>
<td>13</td>
<td>38</td>
</tr>
<tr>
<td>1 Year (%)</td>
<td>75</td>
<td>67</td>
<td>51</td>
<td>82</td>
</tr>
<tr>
<td>3 Year (%)</td>
<td>40</td>
<td>26</td>
<td>20</td>
<td>51.5</td>
</tr>
</tbody>
</table>
### TABLE 4

Median survivals for proposed (size-based) T-stages (SEER database)

<table>
<thead>
<tr>
<th></th>
<th>All cases (n = 9296)</th>
<th>N0 cases (n = 3756)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>T1 (≤2 cm)</td>
<td>T2 (&gt; 2 to ≤4 cm)</td>
</tr>
<tr>
<td>n (%)</td>
<td>1573 (17)</td>
<td>5097 (55)</td>
</tr>
<tr>
<td>Median (months)</td>
<td>24</td>
<td>15</td>
</tr>
<tr>
<td>1 Year (%)</td>
<td>70</td>
<td>58</td>
</tr>
<tr>
<td>3 Year (%)</td>
<td>39</td>
<td>25</td>
</tr>
</tbody>
</table>

*SEER Surveillance, Epidemiology, and End Results*